Triple Negative Breast Neoplasms
"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Descriptor ID |
D064726
|
| MeSH Number(s) |
C04.588.180.788 C17.800.090.500.788
|
| Concept/Terms |
Triple Negative Breast Neoplasms- Triple Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Neoplasms
- ER Negative PR Negative HER2 Negative Breast Neoplasms
- Triple-Negative Breast Cancer
- Breast Cancer, Triple-Negative
- Breast Cancers, Triple-Negative
- Triple-Negative Breast Cancers
- Triple-Negative Breast Neoplasm
- Breast Neoplasm, Triple-Negative
- Breast Neoplasms, Triple-Negative
- Triple Negative Breast Neoplasm
- Triple-Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- ER Negative PR Negative HER2 Negative Breast Cancer
- Triple Negative Breast Cancer
|
Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".
This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 5 | 0 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.
-
Surgical wounding enhances pro-tumor macrophage responses and accelerates tumor growth and lung metastasis in a triple negative breast cancer mouse model. Physiol Rep. 2022 11; 10(21):e15497.
-
NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity. Cancer Lett. 2022 10 28; 547:215884.
-
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP. Pharmacol Res Perspect. 2022 08; 10(4):e00993.
-
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 06 12; 23(1):65.
-
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. Int J Med Sci. 2021; 18(10):2245-2250.
-
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 01; 2(1):66-82.
-
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020 05 15; 11(1):2416.
-
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
-
Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. Ann Surg Oncol. 2019 Dec; 26(13):4782-4790.
-
Increases in Tumor N-Glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. Proteomics Clin Appl. 2019 01; 13(1):e1800014.